All In Biotech

Drug Trial Radar · NCT04416984

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

May 21, 2020

Primary completion

Feb 2029

Study completion May 2029

Sponsor

Lead sponsor
Allogene TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm, open label, multicenter Phase 1/2 study evaluating ALLO-501A in adult subjects with R/R LBCL and CLL/SLL. The purpose of the ALPHA2 study is to assess the safety, efficacy, and cell kinetics of ALLO-501A in adults with relapsed or refractory large B-cell lymphoma and assess the safety of ALLO-501A in adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.

Conditions

  • Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

Interventions

  • ALLO-501AGenetic

    ALLO-501A is an allogeneic CAR T cell therapy targeting CD19

  • ALLO-647Biological

    ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen

  • FludarabineDrug

    Chemotherapy for lymphodepletion

  • CyclophosphamideDrug

    Chemotherapy for lymphodepletion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1a: Proportion of subjects experiencing Dose Limiting Toxicities (DLT) at increasing doses of ALLO-501ATime frame: 28 days
  2. Phase 1a: Proportion of subjects experiencing Dose Limiting Toxicity with ALLO-647 in combination with fludarabine/cyclophosphamide administered prior to ALLO-501ATime frame: 33 days
  3. Phase 1b: Frequency and severity of ALLO-501A treatment-emergent adverse events (AEs), serious AEs, and AEs of special interestTime frame: Up to 60 months
  4. Phase 2: Overall Response Rate (ORR) assessed per Independent Review Committee (IRC)Time frame: Up to 60 months

Locations

29 sites in 3 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • Mayo Clinic Hospital

    Phoenix, Arizona

  • City of Hope

    Duarte, California

  • UCLA Medical Center

    Los Angeles, California

  • Stanford Cancer Institute

    Palo Alto, California

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • Yale School of Medicine

    New Haven, Connecticut

  • University of Miami

    Miami, Florida

  • Advent Health

    Orlando, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Northside Hospital - Atlanta

    Atlanta, Georgia

  • Augusta University

    Augusta, Georgia

  • Loyola University Medical Center

    Maywood, Illinois

  • Norton Cancer Institute

    Louisville, Kentucky

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Providence Portland Medical Center

    Portland, Oregon

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania

  • Avera Medical

    Sioux Falls, South Dakota

  • Vanderbilt Ingram Cancer Center

    Nashville, Tennessee

  • St. David's South Austin Medical Center

    Austin, Texas

  • Texas Oncology

    Dallas, Texas

  • MD Anderson Cancer Center - University of Texas

    Houston, Texas

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • St. Vincent's Hospital Melbourne

    Fitzroy, Victoria, Australia

  • QEII Health Sciences Centre-VG Site

    Halifax, Nova Scotia, Canada

  • CHU de Québec -Université Laval; Hôpital de l'Enfant-Jésus

    Québec, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.